Skip to main content

Table 2 Baseline characteristics of participants

From: Double blind randomized placebo-controlled trial on the effects of testosterone supplementation in elderly men with moderate to low testosterone levels: design and baseline characteristics [ISRCTN23688581]

 

Testosterone (n = 120)

Placebo (n = 117)

Age (yr)

67.3 ± 5.1

67.5 ± 5.0

Weight (Kg)

86.1 ± 13.3

84.4 ± 13.6

Body Mass Index (kg/m2)

27.54 ± 3.85

27.20 ± 3.90

Smokers

21 (17.5)

15 (12.8)

Alcohol users

99 (82.5)

85 (77.3)

Hypertension

75 (62.5)

69 (59)

Systolic Blood Pressure (mm/Hg)

156.2 ± 23.2

151.1 ± 22.6

Diastolic Blood Pressure (mm/Hg)

89.8 ± 12.0

86.8 ± 11.7

Pulse Pressure (mm/Hg)

66.4 ± 15.9

64.3 ± 15.2

Pulse Wave Velocity (m/s)

10.00 ± 2.51

9.53 ± 2.66

Total Testosterone (nmol/L)

10.93 ± 2.06

10.50 ± 1.89

Free Testosterone (nmol/L)

0.22 ± 0.05

0.21 ± 0.05

Bioavailable Testosterone (nmol/L)

5.23 ± 1.15

5.04 ± 1.20

SHBG (nmol/L)

33.17 ± 10.59

32.90 ± 10.38

Albumin (g/L)

43.94 ± 2.31

43.80 ± 2.38

Cholestrol (mmol/L)

5.61 ± 0.99

5.50 ± 0.97

HDL (mmol/L)

1.16 ± 0.28

1.16 ± 0.29

LDL (mmol/L)

3.92 ± 0.91

3.80 ± 0.87

Insuline (mIU/L)

10.14 ± 9.50

8.73 ± 5.41

C-reactive proteine (mg/L)

4.27 ± 6.56

4.09 ± 6.97

PSA (μg/L)

1.54 ± 1.1

1.63 ± 1.1

Creatinine (μmol/L)

93.35 ± 18.0

93.72 ± 15.2

ASAT (U/L)

22.98 ± 8.1

24.21 ± 12.2

ALAT (U/L)

26.36 ± 11.0

26.74 ± 13.6

AF (U/L)

71.57 ± 19.2

69.91 ± 17.9

GGT (U/L)

29.51 ± 15.751

30.18 ± 19.9

Hemoglobine (mmol/L)

9.18 ± 0.5

9.14 ± 0.6

Hematocrit (%)

0.45 ± 0.0

0.45 ± 0.0

Prostate Volume (ultra sound) (cc)

28.20 ± 12.4

27.6 ± 9.8

IPSS

6.38 ± 5

6.50 ± 4.8

  1. Values are means or numbers with S.D. or percentage in parentheses.